Psoriatic Arthritis

Percentage of Psoriatic Arthritis Patients Taking Disease-Modifying Antirheumatic Drug Therapy (2015-2019)

Percentage of Psoriatic Arthritis Patients Taking Disease-Modifying Antirheumatic Drug Therapy (N=1819)

2016-2020

DMARDs include both biologic and non-biologic agents.

American College of Rheumatology guidelines recommend that psoriatic arthritis patients be treated with disease-modifying antirheumatic drug (DMARD) therapy. More than 94% of psoriatic arthritis patients who were seen in the Department of Rheumatology at least 2 times during the years 2016–2020 were treated with DMARD therapy. Reasons for not prescribing DMARD therapy for the small percentage of patients not on DMARDs included disease remission, refusal of treatment, and contraindications to DMARD therapy. In any given year, between 93% and 96% of patients were on a DMARD.